SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Vitrivax Announces $87 Million Series C Financing for Lyme Vaccine Candidate

Vitrivax announced a $87 million Series C financing to advance its Lyme disease vaccine candidate.

LLY

Related stories